Pardes Biosciences, Inc.
PRDSNASDAQHealthcare
$2.18
+$0.02(+0.93%)
Market Cap$135185724
P/E Ratio—
52W High$3.67
52W Low$0.75
Pardes Biosciences, Inc. (PRDS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PRDS · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2023Report Date: Aug 4, 2023EPS Actual
$0.18
Est. -$0.34 · +152.9%
Revenue
—
Fiscal Period
Q3 FY2023
FY ends December
Report Date
Aug 4, 2023
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
PRDS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $0.86B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$0.86B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 2, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 3, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Mar 12, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 6, 2023 | -$0.27 | — | — | — | — | — |
| ▲ Q3 FY2023 | Aug 4, 2023 | -$0.34 | $0.18 | +152.9% | — | — | — |
| ▼ Q2 FY2023 | May 5, 2023 | $0.39 | $0.30 | -23.1% | — | — | — |
| ▼ Q1 FY2023 | Mar 14, 2023 | $0.58 | $0.41 | -29.3% | — | — | — |
| ▼ Q4 FY2022 | Nov 7, 2022 | $0.49 | $0.40 | -18.4% | — | — | — |
Q3 FY2024
Aug 2, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 3, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 12, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 6, 2023
EPS Actual
—
EPS Est.
-$0.27
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 4, 2023Beat
EPS Actual
$0.18
EPS Est.
-$0.34
EPS Surpr.
+152.9%
Revenue
—
Q2 FY2023
May 5, 2023Miss
EPS Actual
$0.30
EPS Est.
$0.39
EPS Surpr.
-23.1%
Revenue
—
Q1 FY2023
Mar 14, 2023Miss
EPS Actual
$0.41
EPS Est.
$0.58
EPS Surpr.
-29.3%
Revenue
—
Q4 FY2022
Nov 7, 2022Miss
EPS Actual
$0.40
EPS Est.
$0.49
EPS Surpr.
-18.4%
Revenue
—
No analyst estimates available for PRDS.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2023 | Aug 4, 2023 | +152.9% | $2.13 | $2.14 | +0.47% |
| ▼ Q2 FY2023 | May 5, 2023 | -23.1% | $1.90 | $1.90 | +0.00% |
| ▼ Q1 FY2023 | Mar 14, 2023 | -29.3% | $1.23 | $1.30 | +5.69% |
| ▼ Q4 FY2022 | Nov 7, 2022 | -18.4% | $1.14 | $1.14 | +0.00% |
| ▲ Q3 FY2022 | Aug 15, 2022 | +23.1% | $3.02 | $2.86 | -5.30% |
| ▼ Q1 FY2022 | Mar 29, 2022 | -70.8% | $6.81 | $6.97 | +2.35% |
| — Q4 FY2021 | Dec 31, 2021 | — | $17.02 | $16.37 | -3.82% |
| — Q4 FY2021 | Nov 12, 2021 | — | $12.49 | $12.48 | -0.08% |
Q3 FY2023+0.47%
Report Date
Aug 4, 2023
EPS Beat/Miss
+152.9%
Price Before
$2.13
Price After
$2.14
Q2 FY2023+0.00%
Report Date
May 5, 2023
EPS Beat/Miss
-23.1%
Price Before
$1.90
Price After
$1.90
Q1 FY2023+5.69%
Report Date
Mar 14, 2023
EPS Beat/Miss
-29.3%
Price Before
$1.23
Price After
$1.30
Q4 FY2022+0.00%
Report Date
Nov 7, 2022
EPS Beat/Miss
-18.4%
Price Before
$1.14
Price After
$1.14
Q3 FY2022-5.30%
Report Date
Aug 15, 2022
EPS Beat/Miss
+23.1%
Price Before
$3.02
Price After
$2.86
Q1 FY2022+2.35%
Report Date
Mar 29, 2022
EPS Beat/Miss
-70.8%
Price Before
$6.81
Price After
$6.97
Q4 FY2021-3.82%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$17.02
Price After
$16.37
Q4 FY2021-0.08%
Report Date
Nov 12, 2021
EPS Beat/Miss
—
Price Before
$12.49
Price After
$12.48
Avg Beat Reaction-2.42%
Avg Miss Reaction+2.01%
Beat Rate2 / 8 quarters
Largest Move+5.69% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PRDS ends December
Pardes Biosciences, Inc. (PRDS) most recently reported earnings on August 4, 2023 for Q3 FY2023, posting EPS of $0.18 — beating the analyst consensus of $-0.34 by +152.9%. The next PRDS earnings date is expected around September 1, 2026.
Each quarter, investors track PRDS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PRDS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PRDS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PRDS earnings · 5 questionsPardes Biosciences, Inc.'s next earnings report is expected around September 1, 2026. PRDS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PRDS historically reports after market close (AMC).
PRDS earnings datewhen is PRDS earningsPRDS next earnings datewhen does PRDS report earningsPRDS earnings calendar
▸ Source: FMP · Pardes Biosciences, Inc. SEC filings · US GAAP · Pardes Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026